Cargando…

Markers of increased atherosclerotic risk in patients with chronic kidney disease: a preliminary study

BACKGROUND: The prevalence of chronic kidney disease is rising continuously. Cardiovascular disease is among leading causes of death and premature mortality of patients with chronic kidney disease. Even the earliest stages of chronic kidney disease are associated with higher risk of subsequent coron...

Descripción completa

Detalles Bibliográficos
Autores principales: Gluba-Brzózka, Anna, Michalska-Kasiczak, Marta, Franczyk, Beata, Nocuń, Marek, Toth, Peter, Banach, Maciej, Rysz, Jacek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4739105/
https://www.ncbi.nlm.nih.gov/pubmed/26843213
http://dx.doi.org/10.1186/s12944-016-0191-x
_version_ 1782413701523963904
author Gluba-Brzózka, Anna
Michalska-Kasiczak, Marta
Franczyk, Beata
Nocuń, Marek
Toth, Peter
Banach, Maciej
Rysz, Jacek
author_facet Gluba-Brzózka, Anna
Michalska-Kasiczak, Marta
Franczyk, Beata
Nocuń, Marek
Toth, Peter
Banach, Maciej
Rysz, Jacek
author_sort Gluba-Brzózka, Anna
collection PubMed
description BACKGROUND: The prevalence of chronic kidney disease is rising continuously. Cardiovascular disease is among leading causes of death and premature mortality of patients with chronic kidney disease. Even the earliest stages of chronic kidney disease are associated with higher risk of subsequent coronary heart disease. The aim of this study was to determine markers of increased risk of atherosclerosis in CKD. METHODS: The study group consisted of a total of 80 patients (20 patients with stage I/II CKD, 20 with stage III CKD, 20 stage IV CKD and 20 stage V/dialysis) and 24 healthy volunteers. Levels of proteins (osteoprotegerin, osteopontin, osteocalcin, matrix γ-carboxyglutamic acid protein, fetuin A, MMP-2, MMP-9, TIMP-1, TIMP-2) and biochemical parameters were measured to analyse their influence on atherosclerosis risk in CKD patients. Cardiac echocardiography was performed to assess structural integrity and function, presence of left ventricular hypertrophy and systolic and diastolic function dysfunction. RESULTS: This study shows that the prevalence of ventricular hypertrophy (95.3 %) and diastolic dysfunction (93.2 %) in CKD patients is high. Also E/E’ ratio was significantly higher (13.6 ± 4.4, p = 0.001), tricuspid insufficiency (27.3 in CKD I/II vs. 71.4 in CKD V, p = 0.016), contractile dysfunction (33.3 in CKD I/II vs. 78.9 in CKD V, p = 0.040), mitral valve calcification (0 in CKD I/II vs. 28.6 in CKD V, p = 0.044) and aortic valve calcification (0 in CKD I/II vs. 61.9 in CKD V, p = 0.0008) were significantly more frequent in patients with CKD stage V/dialysis than in other groups. Only MMP-2, MMP-2/TIMP-2 ratio and TIMP-1 differed significantly between groups. CONCLUSIONS: This study shows high prevalence of ventricular hypertrophy and diastolic dysfunction in CKD patients. Contractile dysfunction, mitral and aortic valve calcification in HD patients were significantly more frequent than in patients with other CKD stages. Significantly increased levels of MMP-2, MMP-2/TIMP-2 ratio and lower TIMP-1 suggests that these factors may be involved in the pathogenesis of atherosclerosis in CKD patients.
format Online
Article
Text
id pubmed-4739105
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-47391052016-02-04 Markers of increased atherosclerotic risk in patients with chronic kidney disease: a preliminary study Gluba-Brzózka, Anna Michalska-Kasiczak, Marta Franczyk, Beata Nocuń, Marek Toth, Peter Banach, Maciej Rysz, Jacek Lipids Health Dis Research BACKGROUND: The prevalence of chronic kidney disease is rising continuously. Cardiovascular disease is among leading causes of death and premature mortality of patients with chronic kidney disease. Even the earliest stages of chronic kidney disease are associated with higher risk of subsequent coronary heart disease. The aim of this study was to determine markers of increased risk of atherosclerosis in CKD. METHODS: The study group consisted of a total of 80 patients (20 patients with stage I/II CKD, 20 with stage III CKD, 20 stage IV CKD and 20 stage V/dialysis) and 24 healthy volunteers. Levels of proteins (osteoprotegerin, osteopontin, osteocalcin, matrix γ-carboxyglutamic acid protein, fetuin A, MMP-2, MMP-9, TIMP-1, TIMP-2) and biochemical parameters were measured to analyse their influence on atherosclerosis risk in CKD patients. Cardiac echocardiography was performed to assess structural integrity and function, presence of left ventricular hypertrophy and systolic and diastolic function dysfunction. RESULTS: This study shows that the prevalence of ventricular hypertrophy (95.3 %) and diastolic dysfunction (93.2 %) in CKD patients is high. Also E/E’ ratio was significantly higher (13.6 ± 4.4, p = 0.001), tricuspid insufficiency (27.3 in CKD I/II vs. 71.4 in CKD V, p = 0.016), contractile dysfunction (33.3 in CKD I/II vs. 78.9 in CKD V, p = 0.040), mitral valve calcification (0 in CKD I/II vs. 28.6 in CKD V, p = 0.044) and aortic valve calcification (0 in CKD I/II vs. 61.9 in CKD V, p = 0.0008) were significantly more frequent in patients with CKD stage V/dialysis than in other groups. Only MMP-2, MMP-2/TIMP-2 ratio and TIMP-1 differed significantly between groups. CONCLUSIONS: This study shows high prevalence of ventricular hypertrophy and diastolic dysfunction in CKD patients. Contractile dysfunction, mitral and aortic valve calcification in HD patients were significantly more frequent than in patients with other CKD stages. Significantly increased levels of MMP-2, MMP-2/TIMP-2 ratio and lower TIMP-1 suggests that these factors may be involved in the pathogenesis of atherosclerosis in CKD patients. BioMed Central 2016-02-03 /pmc/articles/PMC4739105/ /pubmed/26843213 http://dx.doi.org/10.1186/s12944-016-0191-x Text en © Gluba-Brzózka et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Gluba-Brzózka, Anna
Michalska-Kasiczak, Marta
Franczyk, Beata
Nocuń, Marek
Toth, Peter
Banach, Maciej
Rysz, Jacek
Markers of increased atherosclerotic risk in patients with chronic kidney disease: a preliminary study
title Markers of increased atherosclerotic risk in patients with chronic kidney disease: a preliminary study
title_full Markers of increased atherosclerotic risk in patients with chronic kidney disease: a preliminary study
title_fullStr Markers of increased atherosclerotic risk in patients with chronic kidney disease: a preliminary study
title_full_unstemmed Markers of increased atherosclerotic risk in patients with chronic kidney disease: a preliminary study
title_short Markers of increased atherosclerotic risk in patients with chronic kidney disease: a preliminary study
title_sort markers of increased atherosclerotic risk in patients with chronic kidney disease: a preliminary study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4739105/
https://www.ncbi.nlm.nih.gov/pubmed/26843213
http://dx.doi.org/10.1186/s12944-016-0191-x
work_keys_str_mv AT glubabrzozkaanna markersofincreasedatheroscleroticriskinpatientswithchronickidneydiseaseapreliminarystudy
AT michalskakasiczakmarta markersofincreasedatheroscleroticriskinpatientswithchronickidneydiseaseapreliminarystudy
AT franczykbeata markersofincreasedatheroscleroticriskinpatientswithchronickidneydiseaseapreliminarystudy
AT nocunmarek markersofincreasedatheroscleroticriskinpatientswithchronickidneydiseaseapreliminarystudy
AT tothpeter markersofincreasedatheroscleroticriskinpatientswithchronickidneydiseaseapreliminarystudy
AT banachmaciej markersofincreasedatheroscleroticriskinpatientswithchronickidneydiseaseapreliminarystudy
AT ryszjacek markersofincreasedatheroscleroticriskinpatientswithchronickidneydiseaseapreliminarystudy